Drug intelligence / Profile preview

GB-K02

Development stage: Preclinical
Lead developer: Shenzhen Kexing Pharmaceuticals
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Subcutaneous, Intravenous

Overview

GB-K02 is a biosimilar fusion protein developed by Kexing Pharmaceutical using its proprietary KX-FUSION platform. It targets the granulocyte colony-stimulating factor (G-CSF) receptor to stimulate the production, maturation, and activation of neutrophils in the bone marrow. The drug is intended for the treatment of neutropenia, a condition characterized by abnormally low levels of neutrophils, which is a common side effect of myelosuppressive chemotherapy. As of the latest pipeline updates, GB-K02 is in the preclinical research stage in China.

Targets

CSF3R (Granulocyte colony-stimulating factor receptor)

Beyond the preview

Go deeper on GB-K02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GB-K02.

Explore the full profile